Condensed Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 27, 2020	Mar. 29, 2019
Net sales	$ 665.8	$ 790.6
Cost of sales	382.0	455.5
Gross profit	283.8	335.1
Selling, general and administrative expenses	231.1	230.2
Research and development expenses	77.4	85.3
Restructuring charges, net	(1.8)	4.2
Losses on divestiture	0.2	0.0
Opioid-related litigation settlement (Note 11)	(16.8)	0.0
Operating (loss) income	(6.3)	15.4
Interest expense	(74.5)	(82.7)
Interest income	3.5	1.5
Other income, net	1.7	16.3
Loss from continuing operations before income taxes	(75.6)	(49.5)
Income tax benefit	(18.9)	(204.7)
(Loss) income from continuing operations	(56.7)	155.2
Income (loss) from discontinued operations, net of income taxes	6.5	(0.3)
Net (loss) income	$ (50.2)	$ 154.9
Basic (loss) earnings per share (Note 5):
Income (loss) from continuing operations, per share	$ (0.67)	$ 1.86
Income from discontinued operations, per share	0.08	0
Net income, per share	$ (0.60)	$ 1.86
Basic weighted-averaged shares outstanding (in shares)	84.2	83.5
Diluted (loss) earnings per share (Note 5):
Income (loss) from continuing operations, per share	$ (0.67)	$ 1.83
Income from discontinued operations, per share	0.08	0
Net income, per share	$ (0.60)	$ 1.83
Diluted weighted-average shares outstanding (in shares)	84.2	84.6
Retained Earnings (Deficit)
Net (loss) income	$ (50.2)	$ 154.9